Details of the presentations are as follows: Discovery of HMPL-A580, a first-in-class antibody-targeted therapy conjugate (ATTC) of a novel PI3K/PIKK inhibitor payload linked to an anti-EGFR antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results